Keytruda’s Tumor-Agnostic Use, Gilead’s Epclusa, Wider Hemlibra Label Now in Line for Approval by Year-End

MSD’s immuno-oncology star Keytruda (pembrolizumab) cleared a key health ministry panel on November 29 for what would be Japan’s first nod for a tumor-agnostic, biomarker-based indication, which targets a gene mutation irrespective of cancer-affected organs. The Pharmaceutical Affairs and Food...read more